Promoted Content Promoted Content

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Lead Product(s): EP395

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: EP395

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Flerie Invest

            Deal Size: $23.6 million Upfront Cash: Undisclosed

            Deal Type: Series A Financing August 18, 2021

            Details:

            The financing secures funds to advance clinical development of EpiEndo’s lead compound EP395, which entered phase I clinical trials in April, through Phase IIa, targeting COPD as a primary indication.